WO2008101723A3 - Pharmaceutical composition containing a cholesterol absorption inhibitor - Google Patents

Pharmaceutical composition containing a cholesterol absorption inhibitor Download PDF

Info

Publication number
WO2008101723A3
WO2008101723A3 PCT/EP2008/001436 EP2008001436W WO2008101723A3 WO 2008101723 A3 WO2008101723 A3 WO 2008101723A3 EP 2008001436 W EP2008001436 W EP 2008001436W WO 2008101723 A3 WO2008101723 A3 WO 2008101723A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol absorption
absorption inhibitor
pharmaceutical composition
composition containing
hydrophilic polymer
Prior art date
Application number
PCT/EP2008/001436
Other languages
French (fr)
Other versions
WO2008101723A2 (en
Inventor
Vesna Kroselj
Matej Smrkolj
Original Assignee
Krka
Vesna Kroselj
Matej Smrkolj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, Vesna Kroselj, Matej Smrkolj filed Critical Krka
Priority to EP08715987A priority Critical patent/EP2120882A2/en
Publication of WO2008101723A2 publication Critical patent/WO2008101723A2/en
Publication of WO2008101723A3 publication Critical patent/WO2008101723A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Abstract

The present invention relates to a pharmaceutical composition comprising at least one cholesterol absorption inhibitor in amorphous form and at least one hydrophilic polymer, wherein the amorphous cholesterol absorption inhibitor is finely distributed within the hydrophilic polymer or at least one amorphous cholesterol absorption inhibitor and at least one hydrophilic polymer are dispersed onto a carrier.
PCT/EP2008/001436 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor WO2008101723A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08715987A EP2120882A2 (en) 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SIP-200700043 2007-02-23
SI200700043 2007-02-23

Publications (2)

Publication Number Publication Date
WO2008101723A2 WO2008101723A2 (en) 2008-08-28
WO2008101723A3 true WO2008101723A3 (en) 2008-11-27

Family

ID=39710560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/001436 WO2008101723A2 (en) 2007-02-23 2008-02-22 Pharmaceutical composition containing a cholesterol absorption inhibitor

Country Status (2)

Country Link
EP (1) EP2120882A2 (en)
WO (1) WO2008101723A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
EA022269B1 (en) 2007-12-10 2015-12-30 Рациофарм Гмбх Pharmaceutical formulation comprising ezetimibe
TR200806302A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Solubility and stability enhancing pharmaceutical formulation.
TR200806300A2 (en) * 2008-08-22 2010-03-22 B�Lg�� Mahmut Solubility enhancing pharmaceutical formulation
NZ592194A (en) * 2008-09-17 2013-04-26 Mylan Inc Reversed wet granulation process for preparing granulates and pharmaceutical products containing them
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
EP2229938B9 (en) 2009-03-13 2012-04-25 Sanovel Ilac Sanayi ve Ticaret A.S. Ezetimibe compositions
TR200904500A2 (en) 2009-06-10 2009-10-21 Öner Levent Methods and pharmaceutical formulations for the preparation of ezetimibe nanocrystals.
WO2011002424A2 (en) * 2009-07-02 2011-01-06 Bilgic Mahmut Solubility and stability enchancing pharmaceutical formulation
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
EP2448564A2 (en) * 2009-07-02 2012-05-09 Bilgic Mahmut Solubility enhancing pharmaceutical formulation
EP2368543A1 (en) * 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Method of preparing a granulated pharmaceutical composition comprising simvastatin and/or ezetimibe
TR201009397A2 (en) * 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Pharmaceutical compositions containing rosuvastatin.
WO2011139256A2 (en) * 2010-05-04 2011-11-10 Bilgic Mahmut Stable rosuvastatin formulations
EP2468258A1 (en) 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
TWI586380B (en) * 2013-12-18 2017-06-11 夢製藥公司 Pharmaceutical combination preparation comprising a hmg-coa reductase inhibitor and a cholesterol absorption inhibitor
KR20150079373A (en) 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
KR101834559B1 (en) 2015-02-27 2018-03-06 한미약품 주식회사 Solid composite formulation for oral administration comprising ezetimibe and rosuvastatin
CN105287513A (en) * 2015-10-23 2016-02-03 浙江永宁药业股份有限公司 Ezetimibe medicine composition and preparation method thereof
CN105213342A (en) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 Ezetimibe sheet
CN105310993A (en) * 2015-11-17 2016-02-10 深圳信立泰药业股份有限公司 Pharmaceutical composition containing ezetimibe and preparation method of pharmaceutical composition
JP2017210455A (en) * 2016-05-27 2017-11-30 ニプロ株式会社 Ezetimibe-containing pharmaceutical composition
JP7115825B2 (en) * 2017-06-28 2022-08-09 日医工株式会社 Oral formulation containing ezetimibe and its manufacturing method
CN109718215A (en) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 A kind of Ezetimibe piece
CN115252565B (en) * 2022-05-30 2023-09-19 国药集团致君（深圳）制药有限公司 Ezetimibe tablet and preparation process and dissolution evaluation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008068762A2 (en) * 2006-12-07 2008-06-12 Noah Ben-Shalom Chitosan formulation for cholesterol reduction in humans

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134604A1 (en) * 2005-06-15 2006-12-21 Hetero Drugs Limited Combination composition of cholesterol absorption inhibitor and 3-hydroxy-3-methylglutaryl-coenzyme a (hmg-coa) reductase inhibitor
WO2006138163A2 (en) * 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008068762A2 (en) * 2006-12-07 2008-06-12 Noah Ben-Shalom Chitosan formulation for cholesterol reduction in humans

Also Published As

Publication number Publication date
EP2120882A2 (en) 2009-11-25
WO2008101723A2 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
WO2008101723A3 (en) Pharmaceutical composition containing a cholesterol absorption inhibitor
EP2017280A4 (en) Metallocene complex and polymerization catalyst composition containing the same
EP1995282A4 (en) Microparticle-containing viscoelastic layer, and pressure-sensitive adhesive tape or sheet
WO2005118008A3 (en) Compositions and articles containing a crosslinked polymer matrix and an immobilized active liquid, as well as methods of making and using the same
WO2007067625A3 (en) Bioabsorbable surgical composition
EP2053589A4 (en) Active matrix substrate, and display device having the substrate
EP2166058B8 (en) Friction material composition, and friction material produced therewith
EP2189481A4 (en) Fluorine-containing polymer and surface modifier containing the same as active ingredient
WO2007077562A3 (en) Antiseptic compositions and methods of using same
WO2008122967A3 (en) An oral pharmaceutical composition
EP2153838A4 (en) Anti-norovirus agent, and composition comprising the same
WO2009106717A3 (en) Compounds with a guanidine structure and use thereof for as organopolysiloxane polycondensation catalysts
IL187163A0 (en) Novel fluorene derivatives, composition containing said derivatives and the use thereof
EP1980320A4 (en) Photocatalyst material and, containing the same, photocatalyst composition and photocatalyst product
IL205406A0 (en) Alpha - (n - sulfonamido) acetamide compound, composition comprising the same and uses thereof
WO2008124682A3 (en) Oxygen-scavenging materials and articles formed therefrom
WO2005079827A3 (en) Antitumor agent
EP2133382A4 (en) Polymer, and film or sheet comprising the same
EP2099605A4 (en) Composition and articles containing cross-liinked polymer matrix and immobilized active liquid, and methods of making same
WO2008064259A3 (en) Solid dispersion composition comprising fluvastatin
WO2006099232A3 (en) Antimicrobial pet wipes
WO2008142569A3 (en) Topical compositions containing magaldrate
EP2274393A4 (en) Adhesive composition having non-tacky microspheres and sheets made therefrom
WO2010118123A3 (en) Anaerobic adhesive and sealant compositions in film form, film spool assemblies containing such compositions in film form and preapplied versions thereof on matable parts
EP2245091A4 (en) Nanoparticle dispersion, compositions containing the same, and articles made therefrom

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08715987

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008715987

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE